Related Experiment Video
Updated: Jun 13, 2025
Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
Identifying hub genes for chemo-radiotherapy sensitivity in cervical cancer: a bi-dataset in silico analysis
Yanhong Wang1, Yi Ouyang2, Xinping Cao2
1Department of Radiotherapy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian, China.
Purpose:
To identify the hub genes that associated with chemo-radiotherapy sensitivity for cervical cancer and to explore the relationship between hub genes and various cellular processes and potential mechanism of cervical cancer.
Methods:
The gene expression data of 21 patients with CESC and the mRNA expression profiles of 296 patients with CESC were obtained from the Gene Expression Omnibus(GEO) and The Cancer Genome Atlas (TCGA) databases, respectively. The potential functions and regulatory mechanisms of differentially expressed genes (DEGs) were identified using GO and KEGG enrichment analyses. Hub genes were identified using random survival forest analysis. The relationship between hub genes and various cellular processes was comprehensively analyzed. The expression of hub genes was assessed using clinical data extracted from the Human Protein Atlas (HPA) database.
Results:
A total of 139 and 13 DEGs were found to be upregulated and downregulated, respectively, in CESC. The six hub genes, namely, SELP, PIM2, CCL19, SDS, NRP1, and SF3A2, were significantly correlated with immune cell infiltration, chemotherapy sensitivity, disease-related genes, and enriched signaling pathways (all p-value < 0.05). A nomogram and calibration curve were generated using the six hub genes to predict prognosis with high accuracy. A regulatory network comprising TFs (ZBTB3) and mRNAs (NRP1/PIM2/SELP) and several competitive endogenous RNA (ceRNA) networks comprising mRNAs, miRNAs, and lncRNAs were constructed. Data from HPA indicated that the protein expression of the six hub genes differed significantly between patients with CESC and healthy individuals.
Conclusion:
Upregulation of SELP, PIM2, CCL19, SDS, NRP1, and SF3A2 is associated with radiotherapy sensitivity and is involved in various cellular processes in CESC. These six genes may serve as biomarkers for predicting the radiotherapy response and prognosis in patients with CESC.
Insights
Six hub genes, including SELP and PIM2, are linked to chemo-radiotherapy sensitivity in cervical cancer (CESC). These genes may predict treatment response and patient prognosis, offering potential biomarkers for improved outcomes.
Area of Science:
- Oncology
- Genetics
- Biomarkers
Background:
- Cervical cancer (CESC) poses a significant global health challenge.
- Identifying reliable biomarkers for chemo-radiotherapy sensitivity is crucial for effective treatment strategies.
Purpose of the Study:
- To identify key genes (hub genes) associated with chemo-radiotherapy sensitivity in cervical cancer.
- To explore the functional roles and regulatory mechanisms of these hub genes in CESC progression.
Main Methods:
- Utilized gene expression data from GEO and TCGA databases for CESC patients.
- Employed Gene Ontology (GO) and KEGG pathway analyses for functional enrichment.
- Identified hub genes using random survival forest analysis and validated expression via the Human Protein Atlas (HPA).
Main Results:
- Identified 139 upregulated and 13 downregulated differentially expressed genes (DEGs) in CESC.
- Six hub genes (SELP, PIM2, CCL19, SDS, NRP1, SF3A2) significantly correlated with immune infiltration, chemotherapy sensitivity, and enriched pathways (p < 0.05).
- Developed a predictive nomogram for prognosis with high accuracy and constructed regulatory and ceRNA networks.
Conclusions:
- The identified hub genes (SELP, PIM2, CCL19, SDS, NRP1, SF3A2) are associated with radiotherapy sensitivity in CESC.
- These genes are implicated in various cellular processes and may serve as predictive biomarkers for radiotherapy response and prognosis in cervical cancer patients.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...